touchFEATURE Streamlining Alzheimer’s disease diagnosis: The evolution of fluid biomarkers in clinical practice
Watch leading experts discuss evolving fluid biomarkers for AD and assess current blood biomarkers for diagnosing AD in the clinic.
The potential of fluid biomarkers in Alzheimer’s disease diagnosis
Watch a leading neurochemist outline the emergence of fluid biomarkers for AD and their potential for clinical implementation
view bio and disclosures 1/4 Next ChapterCSF biomarkers in Alzheimer’s disease: From current clinical applications to future perspectives
Watch a leading neurologist discuss the clinical value of current and emerging CSF biomarkers for AD diagnosis
view bio and disclosures 2/4 Next ChapterThe evolving journey of Alzheimer’s disease blood biomarkers in clinical practice
Watch a leading neurologist discuss the clinical accuracy of the most promising blood biomarkers for AD diagnosis
view bio and disclosures 3/4 Next ChapterBlood biomarkers to detect Alzheimer’s disease in primary care and secondary care
Watch an overview of key findings from the BioFINDER study showing the clinical utility of the blood biomarker p-Tau217 for AD diagnosis across clinical settings
view bio and disclosures 4/4 Leave FeedbackOverview & Learning Objectives
Overview
Misdiagnosis of Alzheimer’s disease (AD) is common, with up to 30% patients in specialist clinics and up to 70% of patients in primary care misdiagnosed.1 This limits timely diagnosis, appropriate referral and initiation of AD therapies,2,3 and highlights the need for simple and accurate diagnostic tests for AD.4 Fluid biomarker tests have been developed to help meet this need. Tests for AD-associated proteins including tau and amyloid beta in cerebrospinal fluid correlate well with imaging and autopsy findings.5 However, accessibility is limited to specialist centres since patients must undergo an invasive lumbar puncture procedure.3
In contrast, testing for tau and amyloid beta biomarkers in blood samples is already widely used in clinical trials, and could be readily accessible to patients across clinical care settings.3 For example, studies with the blood biomarker phosphorylated Tau217 showed high diagnostic accuracy for identifying AD among people with cognitive symptoms in both primary and secondary care.2 Recent guidelines have recommended sensitivity and specificity standards for blood biomarker tests, allowing future integration of tests that meet these standard into clinical practice.3
Learning Objectives
After watching this activity, participants should be better able to:
- Recognise the emerging role of blood biomarkers in AD diagnosis
- Understand the diagnostic accuracy of blood biomarkers for AD
- Assess clinical data on blood biomarkers for AD including p-Tau217
Faculty & Disclosures
Prof. Charlotte E. Teunissen
Amsterdam University Medical Center, Amsterdam, The Netherlands
Prof. Charlotte E. Teunissen discloses:
A collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly and Company. Performed contract research or received grants from AC Immune SA, Axon Neuroscience, BioConnect, BIORCHESTRA, Brainstorm Cell Therapeutics, Celgene, EIP Pharma, Eisai, Fujirebio, Grifols, Instant NanoBiosensors, Merck, Novo Nordisk, PeopleBio, Roche, Siemens, Toyama, Vivoryon Therapeutics.
Research of Prof. Charlotte E. Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement No. 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant No. 831434) EPND (IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE), National MS Society (Progressive MS alliance), Alzheimer’s Association, Health~Holland, the Dutch Research Council (ZonMw), Alzheimer’s Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. She is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMw (#73305095007) and Health~Holland, Topsector.
Dr Lorenzo Gaetani
University of Perugia, Perugia, Italy
Dr Lorenzo Gaetani discloses:
Served at scientific advisory boards and/or as a consultant for Almirall, Biogen, Fujirebio, Eli Lilly, Novartis. Gave lectures in symposia sponsored by Eli Lilly, Fujirebio and Siemens Healthineers. Received funding for traveling from Almirall, Biogen, Fujirebio, Eli Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers and Teva.
Dr Sebastian Palmqvist
Skåne University Hospital, Scania & Lund University, Lund Sweden
Dr. Sebastian Palmqvist discloses:
Acquired research support (for the institution) from Avid Technology and ki:elements/ Alzheimer’s Drug Discovery Foundation. In the past 2 years, received consultancy/speaker fees from BioArctic, Biogen, Eisai, Lilly, and Roche.
Received no financial compensation from C2N Diagnostics (neither privately nor to the institution). Owns no stocks and has no financial interest in C2N Diagnostics.
References
- Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022.
- Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. 2024;332:1245-57.
- Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease. Nat Rev Neurol. 2024;20:426-39.
- Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022;21:66-77.
Adverse Events
Adverse Events
Information for HCPs in UAE, Saudi Arabia, and Canada
- Information for HCPs in UAE: For adverse events and safety reporting, please send an email: PV-MEA@lilly.com. For product complaints, please send an email: lbmail_pc_mena@lilly.com. For further information about Lilly and Lilly products please contact us at the below address: UAE: Bldg. 25 - 6th Floor, Dubai Health CareCity, Dubai, UAE, P.O. Box #25319, Tel.: (+971 4)453 7800, Fax: (+971 4) 436 2399.
- Information for HCPs in Saudi Arabia: For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com. 24 /7 mobile: +966 567 868 843 Working hours Tel: +966 11 461 7800 , Ext: 1. For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com. For further information, please contact: Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com.
- Information for HCPs in Canada: For adverse events reporting or product complaints, please call Lilly Canada’s Customer Response Centre at 1-888-545-5972 (Monday to Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). For further information about Lilly Canada and Lilly products please contact us at the below address: Eli Lilly Canada Inc. P.O. Box 73, Exchange Tower 130 King Street West, Suite 900 Toronto, Ontario M5X 1B1 Telephone: 416-694-3221 or 1-800-268-4446 (Monday-Friday, 8 a.m. to 5 p.m. Eastern Time, excluding holidays)
